trending Market Intelligence /marketintelligence/en/news-insights/trending/wbvgsuqadlbro4qg9w3zbw2 content esgSubNav
In This List

Medartis planning Swiss IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Medartis planning Swiss IPO

Switzerland's Medartis Holding AG said Feb. 27 that it is planning an IPO on the SIX Swiss Exchange in the first half of 2018.

The bone implant manufacturer will use proceeds to finance its growth and help raise its international profile.

For 2017, Medartis posted operational EBITDA of CHF19 million, with net revenues of CHF105 million, up 14% year over year.

Vischer AG is acting as legal counsel to Medartis, with Davis Polk assisting on U.S. securities law matters and Quarton International AG as financial adviser.

Zürcher Kantonalbank and Bryan Garnier & Co. are acting as underwriters, joint global coordinators and Joint book runners for the planned IPO, with Kepler Cheuvreux as underwriter and co-manager. Walder Wyss AG is acting as legal counsel to the underwriters.